Neuroleptic malignant syndrome — NMS — is the rare, idiosyncratic, life-threatening reaction to D2 blockade. It is not common, but recognizing it is one of the most important skills in psychiatric pharmacology, because failure to recognize is failure to treat, and untreated NMS can be fatal.
- Class
- Idiosyncratic adverse reaction
- Mechanism
- Hypothesized: rapid central D2 blockade in hypothalamus, basal ganglia, and brainstem → autonomic dysregulation, rigidity, hyperthermia
- FDA indications
- Recognition and management framework
- Key adverse effects
- Hyperthermia (often >40°C), severe muscle rigidity ("lead pipe"), autonomic instability (BP swings, tachycardia, diaphoresis), altered mental status, elevated CK (often >1000), myoglobinuria → renal failure
Black box: Antipsychotic-induced NMS can be fatal — mortality ~5-20% historically; recognition and prompt treatment are essential
Risk factors: high-potency FGA, rapid dose escalation, IM administration, dehydration, agitation, prior NMS episode. Management: discontinue antipsychotic immediately, supportive care (cooling, hydration, electrolytes), dantrolene or bromocriptine for severe cases, ICU-level monitoring. Future antipsychotic use cautious — typically with a clozapine or quetiapine (lower NMS risk) after recovery, slow titration.
The classic tetrad: hyperthermia (often >40°C), severe muscle rigidity ("lead-pipe rigidity" — sustained, not the cogwheeling of parkinsonism), autonomic instability (BP swings, tachycardia, diaphoresis), and altered mental status (delirium, stupor, coma). Add elevated CK — often very high, sometimes above 10,000 — and myoglobinuria producing renal injury. The picture develops over 1-3 days, typically within two weeks of antipsychotic initiation or dose increase.
Neuroleptic malignant syndrome is the catastrophic extreme of dopamine blockade — a hypodopaminergic crisis affecting thermoregulation, muscle, and autonomic function.
Mechanism note: NMS is dopamine blockade taken to a lethal extreme. Recognition of the tetrad — hyperthermia, rigidity, autonomic instability, altered mentation — plus CK elevation drives immediate drug cessation and emergency management.
Risk factors: high-potency FGAs especially, rapid dose escalation, IM administration, dehydration, agitation, prior NMS history. Mortality historically was 5-20%; with early recognition and treatment, lower.
Differential is serotonin syndrome — both have hyperthermia, autonomic instability, altered mental status. NMS develops over days with lead-pipe rigidity and hyporeflexia; serotonin syndrome develops over hours with hyperreflexia, clonus (especially lower extremity), and prominent GI symptoms. Drug history clarifies: NMS — antipsychotic exposure. Serotonin syndrome — serotonergic drug combination, often SSRI plus another agent.
Management is urgent. Discontinue the antipsychotic immediately. ICU-level supportive care: aggressive cooling, hydration to protect renal function, electrolyte correction, BP support, intubation if airway compromised. Dantrolene (skeletal muscle relaxation, helps the rigidity) or bromocriptine (D2 agonist) for severe cases. Treatment can take days to weeks; some patients require prolonged ICU care.
After recovery, future antipsychotic use must be cautious. Clozapine or quetiapine are often chosen — lower NMS recurrence risk. Slow titration. Consider whether the original indication requires antipsychotic at all, or whether an alternative class (mood stabilizer for bipolar, etc.) could substitute. Document the NMS history prominently in the chart and educate the patient — they need to know to alert every future prescriber.